Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

24.01.2005


Even before making the connection between drugs such as Vioxx and heart attacks, many doctors were becoming concerned that the heavily advertised drugs known as COX-2 inhibitors were being over-used, often by patients unlikely to benefit from this costly but innovative pharmaceutical class.



In the January 25, 2005, issue of the Archives of Internal Medicine, researchers from the University of Chicago and Stanford University School of Medicine use data from the National Center for Health Statistics to show that most of the growth in COX-2 use between 1999 and 2002 occurred in patients at little risk for side effects from the drugs COX-2s were developed to replace.

"We found a rapid nationwide shift away from older, inexpensive drugs with better established safety and efficacy to newer, costly drugs with no real history," said study author G. Caleb Alexander, M.D., M.S., instructor of medicine and a member of the MacLean Center for Clinical Medical Ethics at the University of Chicago.


"We pursued our analysis because of concerns that this was an example of overuse of a newer, more expensive class of medications," said co-author Randall S. Stafford, M.D., Ph.D., associate professor and Director of the Program on Prevention Outcomes and Practice at Stanford University. "As with other examples in the treatment of high blood pressure, diabetes and some infections, there appears to be a tendency for new drugs to be used in a wider array of situations than supported by scientific studies."

The COX-2 inhibitors, introduced early in 1999, were widely promoted as "super aspirin." Ordinary aspirin blocks both COX-2, which triggers inflammation, as well as COX-1, which protects the stomach lining and helps to decrease the risk of GI bleeds and stomach ulcers. These newer and far more expensive drugs were designed to target only COX-2 and to be used to treat patients with chronic inflammatory disorders such as arthritis.

The COX-2 inhibitors are no more effective in relieving pain than aspirin, ibuprofen, or any of the traditional non-steroidal anti-inflammatory drugs (NSAIDs), but they cause fewer of the gastrointestinal side effects that often trouble long-term high-dose NSAID users. In exchange for reduced GI risk, however, they cost 10 to 15 times as much as the drugs they replaced.

Within a year of being introduced, these drugs were bringing in billions of dollars of annual revenue. These drugs were also heavily promoted to physicians and to the general public. In 2000 alone, Vioxx was the most aggressively promoted drug on the market, including $161 million of direct-to-consumer advertising.

The researchers wondered how many of these prescriptions were going to patients who were not likely to benefit from them -- those with minimal risk of the gastrointestinal problems that can be caused by standard anti-inflammatory drugs.

They used data from two large nationally representative surveys of patient visits to doctors’ offices. Then they looked at the use of NSAIDs versus COX-2 prescriptions and compared them to treatment guidelines that stratify patients into different treatment groups based on the risks of gastrointestinal symptoms.

The guidelines recommend that patients with "very low risk" of GI problems (31% of patients in this study) or "low risk" (42%) receive traditional NSAIDs. Patients with "moderate risk" (25%) could receive COX-2s or NSAIDs depending on the expected length of treatment. Patients at "high risk" (2%) should take COX-2 inhibitors.

They authors found that the COX-2 inhibitors were frequently prescribed for all four groups and that they quickly gained market share, bounding from nowhere to 35 percent of anti-inflammatory prescriptions examined in 1999, the year they were introduced, to 61 percent by 2001.

They also found that most people who received prescriptions were at very low or low risk for GI bleeds and thus did not really need a COX-2 inhibitor. Despite the guidelines, 1.7 million, or 12 percent of patients at very low risk, received COX-2 prescriptions in 1999. That number increased to 7.6 million or 40 percent of very low risk patients by 2001 before declining slightly in 2002. At the same time, 6.8 million patients, or 40 percent of those at low risk, got COX-2 drugs in 1999, which increased to 17.6 million or 66 percent of low risk patients in 2002.

Over time, growth in COX-2 inhibitor use was most likely to come from those users least likely to benefit from these drugs.

By 2000, more patients were receiving COX-2 inhibitors than standard NSAIDs, including an estimated 16 million people suffering from congestive heart failure, or liver or kidney dysfunction, which are considered relative contra-indications to both COX-2s or NSAIDs.

"What we saw was widespread, rapid adoption of an interesting and promising but expensive and largely untested medication by millions of people with little or nothing to gain from long-term use," Alexander said. "The findings," the authors note, "demonstrate the challenge of limiting innovative therapies to the settings in which they are initially targeted and maximally cost-effective."

Carolanne Dai of the University of Chicago was the lead author of the paper. The research was supported by the MacLean Center for Clinical Medical Ethics at the University of Chicago, the National Institute of Aging, and the Agency for Healthcare Research and Quality.

John Easton | EurekAlert!
Further information:
http://www.uchospitals.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>